Physician profile
David W Dick
NPI 1609819606
$1,969.58
in general payments reported to CMS, 2019-2025
36 companies · $168 in 2025
The $168 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.08 · 2020: $66.78 · 2021: $376 · 2022: $507 · 2023: $392 · 2024: $432 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $991.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $407.03 | 2021-2024 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $140.18 | 2021-2024 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $133.67 | 2022-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $131.94 | 2022-2023 | |
| Astrazeneca Pharmaceuticals Lp | $83.63 | 2024-2025 | Airsupra |
| Lilly USA, LLC | $80.32 | 2021-2025 | Jardiance, Emgality, Reyvow |
| Inspire Medical Systems, INC. | $76.33 | 2024-2025 | Inspire |
| Pfizer INC. | $73.25 | 2019-2024 | |
| Exact Sciences Corporation | $73.14 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $71.76 | 2020-2023 | Veozah |
| Axsome Therapeutics, INC. | $64.92 | 2024-2025 | Sunosi, Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $54.50 | 2021-2025 | |
| Antares Pharma, INC. | $48.33 | 2022-2024 | Xyosted |
| Janssen Pharmaceuticals, INC | $47.86 | 2019-2021 | |
| Esperion Therapeutics, INC. | $41.59 | 2022-2024 | Nexletol |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $37.12 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $35.64 | 2023 | |
| Mayne Pharma Commercial LLC | $31.26 | 2023 | |
| Amgen INC. | $30.42 | 2022-2024 | Repatha, Otezla |
| Organon LLC | $29.32 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $28.39 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $27.64 | 2022-2023 | Livalo, Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.82 | 2021-2025 | Xifaxan |
| Tolmar, INC. | $22.89 | 2023 | |
| Shield Therapeutics INC | $17.71 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $16.86 | 2021 | |
| Almatica Pharma LLC | $15.78 | 2021 | |
| Sumitomo Pharma America, INC. | $15.59 | 2025 | Gemtesa |
| Dexcom, INC. | $15.11 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.77 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.66 | 2023 | Quviviq |
| Mylan Specialty L.P. | $13.10 | 2021 | |
| Abbott Laboratories | $12.98 | 2022 | |
| Amarin Pharma, INC. | $12.95 | 2021 | |
| Merck Sharp & Dohme LLC | $12.93 | 2021 | |
| Eisai INC. | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.